- Home
- Publications
- Publication Search
- Publication Details
Title
The future of targeted kinase inhibitors in melanoma
Authors
Keywords
-
Journal
PHARMACOLOGY & THERAPEUTICS
Volume 239, Issue -, Pages 108200
Publisher
Elsevier BV
Online
2022-05-02
DOI
10.1016/j.pharmthera.2022.108200
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
- (2022) Janice M. Mehnert et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
- (2022) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-checkpoint inhibitors: long-term implications of toxicity
- (2022) Douglas B. Johnson et al. Nature Reviews Clinical Oncology
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma
- (2022) Anna Han et al. ONCOGENE
- Targeted Therapy for Melanomas Without BRAF V600 Mutations
- (2022) Christian Menzer et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response
- (2022) Jesse Yu et al. PHARMACOLOGY & THERAPEUTICS
- Roles of the BAP1 tumor suppressor in cell metabolism
- (2021) Anna Han et al. CANCER RESEARCH
- Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease
- (2021) Charlotte Pandiani et al. CELL DEATH AND DIFFERENTIATION
- Roles and mechanisms of BAP1 deubiquitinase in tumor suppression
- (2021) Louis Masclef et al. CELL DEATH AND DIFFERENTIATION
- Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
- (2021) José María Piulats et al. JOURNAL OF CLINICAL ONCOLOGY
- A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
- (2021) Ester Simeone et al. Journal of Translational Medicine
- Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
- (2021) Claudio Tabolacci et al. Biomedicines
- Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
- (2021) Khanh B. Tran et al. BMC CANCER
- Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- (2021) Justine S. Paradis et al. CLINICAL CANCER RESEARCH
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Neoadjuvant Cytoreductive Treatment with BRAF/MEK Inhibition of prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR
- (2021) Stéphanie A. Blankenstein et al. ANNALS OF SURGERY
- Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway
- (2021) Lili Mao et al. EUROPEAN JOURNAL OF CANCER
- Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
- (2021) Luca Tonella et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
- (2021) Amod A. Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
- (2021) Ivana Yen et al. NATURE
- Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study
- (2021) Caroline A. Nebhan et al. ONCOLOGIST
- CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory
- (2021) Emily J Lelliott et al. Cancer Discovery
- Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
- (2021) Emily J. Lelliott et al. Frontiers in Immunology
- Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
- (2021) Pier Francesco Ferrucci et al. Cancers
- RTK Inhibitors in Melanoma: From Bench to Bedside
- (2021) Malak Sabbah et al. Cancers
- LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
- (2021) P.A. Ascierto et al. ANNALS OF ONCOLOGY
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
- (2021) A. Ribas et al. ANNALS OF ONCOLOGY
- Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection
- (2021) Robert J. Torphy et al. ANNALS OF SURGICAL ONCOLOGY
- Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- (2021) Yujue Wang et al. CANCER CELL
- 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
- (2021) Paolo A. Ascierto et al. CLINICAL CANCER RESEARCH
- Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
- (2021) Philippe Saiag et al. EUROPEAN JOURNAL OF CANCER
- Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up
- (2021) Elin Aamdal et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases.
- (2021) Elizabeth M. Burton et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.
- (2021) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.
- (2021) Victoria Atkinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis
- (2021) Kenneth K. Cho et al. MELANOMA RESEARCH
- Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
- (2021) Kelsey W. Nassar et al. MOLECULAR CANCER THERAPEUTICS
- A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors
- (2021) Jin‐Ock Kim et al. Molecular Oncology
- Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
- (2021) Bianca J. Lee et al. Nature Chemical Biology
- Recent Advances in the Treatment of Melanoma
- (2021) Brendan D. Curti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
- (2021) Beike Wang et al. ONCOGENE
- The AMP‐dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma
- (2021) Vivian Chua et al. Pigment Cell & Melanoma Research
- Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
- (2021) XuSha Zhou et al. Viruses-Basel
- Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
- (2021) Ilona Berestjuk et al. EMBO Molecular Medicine
- Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
- (2021) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis
- (2021) Theresa Steeb et al. EUROPEAN JOURNAL OF CANCER
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
- (2021) Michele Maio et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
- (2021) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
- (2021) Mª del Carmen Álamo et al. OncoTargets and Therapy
- Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
- (2021) Maria Gonzalez-Cao et al. Nature Communications
- Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
- (2021) Peter Kar Han Lau et al. Journal for ImmunoTherapy of Cancer
- IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
- (2021) Hima Patel et al. Cancers
- A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
- (2021) Alexander N. Shoushtari et al. Cancers
- Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
- (2021) Peter Kar Han Lau et al. Cancers
- Conjunctival Melanoma: Current Treatments and Future Options
- (2020) Joseph M. Grimes et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
- (2020) Axel Hauschild et al. EUROPEAN JOURNAL OF CANCER
- Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
- (2020) Sophie Piperno-Neumann et al. MOLECULAR CANCER THERAPEUTICS
- Harnessing the Power of Proteolysis for Targeted Protein Inactivation
- (2020) Rati Verma et al. MOLECULAR CELL
- Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
- (2020) Alison M. Kurimchak et al. Science Signaling
- Single-cell analysis reveals new evolutionary complexity in uveal melanoma
- (2020) Michael A. Durante et al. Nature Communications
- Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management
- (2020) Daan Jan Willem Rauwerdink et al. ANNALS OF SURGICAL ONCOLOGY
- FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
- (2020) Atish Mohanty et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Systemic Therapy for Melanoma: ASCO Guideline
- (2020) Rahul Seth et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
- (2020) Jayesh Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
- (2020) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.
- (2020) Elisa A. Rozeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
- (2020) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition
- (2020) Mai Q. Nguyen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma
- (2020) Jessica LF Teh et al. MOLECULAR CANCER THERAPEUTICS
- RAF kinase dimerization: implications for drug discovery and clinical outcomes
- (2020) Tilman Brummer et al. ONCOGENE
- Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease
- (2020) Patricia Basurto‐Lozada et al. Pigment Cell & Melanoma Research
- Molecular profiling of driver events in metastatic uveal melanoma
- (2020) Joakim Karlsson et al. Nature Communications
- YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines
- (2020) Yong Joon Kim et al. Scientific Reports
- Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment
- (2020) Angelica Avagliano et al. Frontiers in Oncology
- ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee
- (2020) U. Keilholz et al. ANNALS OF ONCOLOGY
- ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee
- (2020) O. Michielin et al. ANNALS OF ONCOLOGY
- Targeted Therapy in Melanoma and Mechanisms of Resistance
- (2020) Anna M. Czarnecka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma
- (2020) Bennett Yau-Bun Hong et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2
- (2020) Gretchen M. Alicea et al. Cancer Discovery
- Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
- (2020) Jessica L.F. Teh et al. Cancer Immunology Research
- Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
- (2020) Eva Crespo-Rodriguez et al. Journal for ImmunoTherapy of Cancer
- Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
- (2020) Celeste Lebbé et al. Cancers
- Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study
- (2020) Puneet Jain et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
- (2020) Amanda Truong et al. CLINICAL CANCER RESEARCH
- First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis
- (2020) Anna C Pavlick et al. Future Oncology
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma
- (2020) Jane Mattei et al. MELANOMA RESEARCH
- Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma
- (2020) Jeffim N Kuznetsoff et al. MOLECULAR CANCER RESEARCH
- Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
- (2020) Alain P. Algazi et al. NATURE MEDICINE
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
- (2020) Felicity Newell et al. Nature Communications
- Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
- (2020) Italia Falcone et al. Cancers
- Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives
- (2020) Matías Chacón et al. Cancers
- Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
- (2020) Tyler D. Hitchman et al. CLINICAL CANCER RESEARCH
- BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors
- (2020) Anna Han et al. ONCOGENE
- Functional characterization of uveal melanoma oncogenes
- (2020) Jiafang Ma et al. ONCOGENE
- PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
- (2020) Antoni Ribas et al. Nature Communications
- Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity
- (2020) Aayoung Hong et al. Cancer Discovery
- Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
- (2020) Emily J. Lelliott et al. Cancer Immunology Research
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
- (2020) Pier Francesco Ferrucci et al. Journal for ImmunoTherapy of Cancer
- Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
- (2020) Meredith S. Pelster et al. JOURNAL OF CLINICAL ONCOLOGY
- Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
- (2019) Vivian Chua et al. EMBO Molecular Medicine
- Overall survival after treatment for metastatic uveal melanoma
- (2019) Elina S. Rantala et al. MELANOMA RESEARCH
- Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
- (2019) Grant M. Fischer et al. Cancer Discovery
- Direct targeting of Gαq and Gα11 oncoproteins in cancer cells
- (2019) Suvi Annala et al. Science Signaling
- A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma
- (2019) Alain Patrick Algazi et al. Pigment Cell & Melanoma Research
- Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
- (2019) Christiane Margue et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
- (2019) Tian Tian et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma
- (2019) Tikvah K Hayes et al. CANCER RESEARCH
- A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK
- (2019) Xiaodong Feng et al. CANCER CELL
- Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
- (2019) Tae Won Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
- (2019) Fernanda Faião-Flores et al. CLINICAL CANCER RESEARCH
- Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma
- (2019) Ileine M Sanchez et al. MOLECULAR CANCER THERAPEUTICS
- The genetic evolution of metastatic uveal melanoma
- (2019) A. Hunter Shain et al. NATURE GENETICS
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant BRAF ‐targeted therapy in regionally advanced and oligometastatic melanoma
- (2019) Zeynep Eroglu et al. Pigment Cell & Melanoma Research
- C57BL/6 congenic mouse NRAS Q61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo
- (2019) Valérie Petit et al. Pigment Cell & Melanoma Research
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
- (2019) Felicity Newell et al. Nature Communications
- Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
- (2019) Jiayi Yu et al. CLINICAL CANCER RESEARCH
- Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors Through Autocrine FGFR Pathway Activation
- (2019) Victoria E. Wang et al. CLINICAL CANCER RESEARCH
- Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
- (2019) Aasen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
- (2019) Shatha AbuHammad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
- (2019) Anna E. Vilgelm et al. Science Translational Medicine
- Targeting Autophagy in Cancer: Recent Advances and Future Directions
- (2019) Ravi K. Amaravadi et al. Cancer Discovery
- Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
- (2019) Emanuelle M. Rizk et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules
- (2019) Sebastian Bunk et al. BLOOD
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- (2019) Christian Menzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
- (2019) Ryan J. Sullivan et al. MOLECULAR CANCER THERAPEUTICS
- Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
- (2019) Luigi Fattore et al. Cell Death & Disease
- Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
- (2019) Justin C. Moser et al. Cancer Medicine
- Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2019) Jong Yeob Kim et al. Cancers
- Decitabine limits escape from MEK inhibition in uveal melanoma
- (2019) Jessica Gonçalves et al. Pigment Cell & Melanoma Research
- Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
- (2019) Dan A. Erkes et al. Cancer Discovery
- YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression
- (2019) Huapeng Li et al. Cell Reports
- Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
- (2018) Eszter Molnár et al. BMC CANCER
- Toward Minimal Residual Disease-Directed Therapy in Melanoma
- (2018) Florian Rambow et al. CELL
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
- (2018) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma
- (2018) Christopher A. Barker et al. Journal of the National Comprehensive Cancer Network
- Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2018) Michele Maio et al. LANCET ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
- (2018) Rodabe N Amaria et al. LANCET ONCOLOGY
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors
- (2018) Raeeka Khamari et al. Cell Death & Disease
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
- (2018) Gabriele Romano et al. Cancer Discovery
- Chk1 inhibition as a novel therapeutic strategy in melanoma
- (2018) Bor-Jang Hwang et al. Oncotarget
- A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
- (2018) Meghan J. Mooradian et al. OncoImmunology
- ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma
- (2018) Claudia Capparelli et al. CANCER RESEARCH
- Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine
- (2018) Ahmad Tarhini et al. CANCER TREATMENT REVIEWS
- Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.
- (2018) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
- (2018) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting nucleotide exchange to inhibit constitutively active G protein α subunits in cancer cells
- (2018) Michael D. Onken et al. Science Signaling
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma
- (2018) Axel Hauschild et al. JAMA Oncology
- A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
- (2018) Joseph I. Clark et al. Journal for ImmunoTherapy of Cancer
- Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
- (2018) V Urbonas et al. ANNALS OF ONCOLOGY
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
- (2018) Alison M. Schram et al. BRITISH JOURNAL OF CANCER
- The clinical role of the TME in solid cancer
- (2018) Nicolas A. Giraldo et al. BRITISH JOURNAL OF CANCER
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- (2018) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines of care for the management of primary cutaneous melanoma
- (2018) Susan M. Swetter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma
- (2018) Dominic Lapadula et al. MOLECULAR CANCER RESEARCH
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma
- (2018) Oded Sagiv et al. JAMA Ophthalmology
- Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
- (2018) Maartje W. Rohaan et al. Journal for ImmunoTherapy of Cancer
- Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
- (2017) Markus V. Heppt et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease
- (2017) Ioannis Karydis et al. JOURNAL OF SURGICAL ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma
- (2017) Vivian Chua et al. MOLECULAR CANCER RESEARCH
- Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
- (2017) Edward J. Hartsough et al. MOLECULAR CANCER THERAPEUTICS
- Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
- (2017) Hanyin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
- (2017) P Dietrich et al. ONCOGENE
- Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
- (2017) Adil Daud et al. ONCOLOGIST
- Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
- (2017) Alain P. Algazi et al. Pigment Cell & Melanoma Research
- RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma
- (2017) Coralie Dorard et al. Nature Communications
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF V600E Melanoma Lines with Vemurafenib
- (2017) Alexandra Frazao et al. Cancer Immunology Research
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
- (2016) Ajjai Alva et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma
- (2016) Jessica L.F. Teh et al. CANCER RESEARCH
- A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
- (2016) Drew C. Deniger et al. CLINICAL CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
- (2016) Francesco Sabbatino et al. JNCI-Journal of the National Cancer Institute
- Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
- (2016) Amanda R Moore et al. NATURE GENETICS
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
- (2016) G Pathria et al. Cell Death & Disease
- Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy
- (2016) Jinfeng Cao et al. Oncotarget
- Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
- (2016) Francesco Sabbatino et al. JNCI-Journal of the National Cancer Institute
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
- (2016) Zachary A. Cooper et al. OncoImmunology
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
- (2016) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
- (2015) Gry Irene Magnussen et al. BMC CANCER
- Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma
- (2015) Tasha Hughes et al. CANCER BIOLOGY & THERAPY
- ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas
- (2015) C. Capparelli et al. CANCER RESEARCH
- Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma
- (2015) H. Cheng et al. CANCER RESEARCH
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
- (2015) R. D. Carvajal et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
- (2015) H. Kakavand et al. CLINICAL CANCER RESEARCH
- Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma
- (2015) Claudia Capparelli et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
- (2015) Mohammad Atefi et al. Molecular Cancer
- Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
- (2015) I V Fedorenko et al. ONCOGENE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
- (2015) S. D. Bradley et al. Cancer Immunology Research
- Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
- (2015) Blanca Homet Moreno et al. OncoImmunology
- PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
- (2015) Francesco Sabbatino et al. Oncotarget
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
- (2014) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
- (2014) Boris C. Bastian Annual Review of Pathology-Mechanisms of Disease
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 and Oxidative Phosphorylation in Melanoma
- (2014) Y. N. V. Gopal et al. CANCER RESEARCH
- Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFN
- (2014) P.-C. Ho et al. CANCER RESEARCH
- Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
- (2014) L. Ferrari de Andrade et al. CANCER RESEARCH
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
- (2014) G. Chen et al. CLINICAL CANCER RESEARCH
- Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
- (2014) Mark A. Dickson et al. INVESTIGATIONAL NEW DRUGS
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
- (2014) Xiao-Hong Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- The Phosphoinositide 3-Kinase Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
- (2014) E. Musi et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
- (2014) Nabil Amirouchene-Angelozzi et al. Molecular Oncology
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined PKC and MEK inhibition for treating metastatic uveal melanoma
- (2014) M S Sagoo et al. ONCOGENE
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF
- (2014) M. P. Smith et al. Cancer Discovery
- BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
- (2014) S. M. Steinberg et al. Cancer Immunology Research
- MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
- (2014) L. J. Vella et al. Cancer Immunology Research
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11
- (2013) A E Koopmans et al. BRITISH JOURNAL OF CANCER
- Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
- (2013) Patrick A. Ott et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas
- (2013) K. G. Griewank et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
- (2013) C. Posch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
- (2013) S. J. Furney et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells
- (2012) Caroline Bonet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
- (2010) Emanuela Romano et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
- Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma
- (2008) S. Bakalian et al. CLINICAL CANCER RESEARCH
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- A gene regulatory network orchestrates neural crest formation
- (2008) Tatjana Sauka-Spengler et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started